{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:09Z","timestamp":1787020509416,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-025-03989-3","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:57:41Z","timestamp":1760522261000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Shuangshuang","family":"Dou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyin","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buxin","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoni","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"3989_CR1","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. Ca-Cancer J Clin. 2023;73:198\u2013222.","journal-title":"Ca-Cancer J Clin"},{"key":"3989_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112368","author":"S Kodali","year":"2021","unstructured":"Kodali S, Shetty A, Shekhar S, Victor DW, Ghobrial RM. Management of intrahepatic cholangiocarcinoma. J Clin Med. 2021 ;10(11), 2368 . https:\/\/doi.org\/10.3390\/jcm10112368","journal-title":"J Clin Med"},{"key":"3989_CR3","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1245\/s10434-021-09671-y","volume":"28","author":"ZV Fong","year":"2021","unstructured":"Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The clinical management of cholangiocarcinoma in the United States and Europe: a comprehensive and evidence-based comparison of guidelines. Ann Surg Oncol. 2021;28:2660\u201374.","journal-title":"Ann Surg Oncol"},{"key":"3989_CR4","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/jnci\/djq279","volume":"102","author":"AF Gazdar","year":"2010","unstructured":"Gazdar AF, Girard L, Lockwood WW, Lam WL, Minna JD. Lung cancer cell lines as tools for biomedical discovery and research. JNCI J Natl Cancer Inst. 2010;102:1310\u201321.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"3989_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-92491-7","volume":"11","author":"X Bian","year":"2021","unstructured":"Bian X, Cao F, Wang X, Hou Y, Zhao H, Liu Y. Establishment and characterization of a new human colon cancer cell line, PUMC-CRC1. Sci Rep. 2021;11:13122.","journal-title":"Sci Rep"},{"key":"3989_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/aps.2010.214","volume":"32","author":"C Zheng","year":"2011","unstructured":"Zheng C, Sun YH, Ye XL, Chen HQ, Ji HB. Establishment and characterization of primary lung cancer cell lines from Chinese population. Acta Pharmacol Sin. 2011;32:385\u201392.","journal-title":"Acta Pharmacol Sin"},{"key":"3989_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/0008-5472.CAN-06-0594","volume":"67","author":"V Dangles-Marie","year":"2007","unstructured":"Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res. 2007;67:398\u2013407.","journal-title":"Cancer Res"},{"key":"3989_CR8","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc.2016.140","volume":"17","author":"AT Byrne","year":"2017","unstructured":"Byrne AT, Alferez DG, Amant F, Annibali D, Arribas J, Biankin AV, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17:254\u201368.","journal-title":"Nat Rev Cancer"},{"key":"3989_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/cells8050496","author":"K Vaeteewoottacharn","year":"2019","unstructured":"Vaeteewoottacharn K, Pairojkul C, Kariya R, Muisuk K, Imtawil K, Chamgramol Y, et al. Establishment of highly transplantable cholangiocarcinoma cell lines from a patient-derived xenograft mouse model. Cells. 2019 ;8(5), 496. https:\/\/doi.org\/10.3390\/cells8050496","journal-title":"Cells"},{"key":"3989_CR10","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1245\/s10434-019-07649-5","volume":"26","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Luo J, Dong X, Yang F, Zhang M, Zhao J, et al. Establishment and characterization of two novel cholangiocarcinoma cell lines. Ann Surg Oncol. 2019;26:4134\u201347.","journal-title":"Ann Surg Oncol"},{"key":"3989_CR11","first-page":"153","volume":"9","author":"S Sirisinha","year":"1991","unstructured":"Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, Ratanarapee S, Pausawasdi A. Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Asian Pac J Allergy. 1991;9:153\u20137.","journal-title":"Asian Pac J Allergy"},{"key":"3989_CR12","first-page":"1195","volume":"18","author":"S Ma","year":"2007","unstructured":"Ma S, Hu L, Huang XH, Cao LQ, Chan KW, Wang Q, et al. Establishment and characterization of a human cholangiocarcinoma cell line. Oncol Rep. 2007;18:1195\u2013200.","journal-title":"Oncol Rep"},{"key":"3989_CR13","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/sj.bjc.6600440","volume":"87","author":"JL Ku","year":"2002","unstructured":"Ku JL, Yoon KA, Kim IJ, Kim WH, Jang JY, Suh KS, et al. Establishment and characterisation of six human biliary tract cancer cell lines. Br J Cancer. 2002;87:187\u201393.","journal-title":"Br J Cancer"},{"key":"3989_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02478-z","volume":"41","author":"J Zhang","year":"2022","unstructured":"Zhang J, Pan T, Zhou W, Zhang Y, Xu G, Xu Q, et al. Long noncoding RNA LINC01132 enhances immunosuppression and therapy resistance via NRF1\/DPP4 axis in hepatocellular carcinoma. J Exp Clin Cancer Res. 2022;41:270.","journal-title":"J Exp Clin Cancer Res"},{"key":"3989_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ejpb.2007.04.021","volume":"68","author":"J Jo","year":"2008","unstructured":"Jo J, Tabata Y. Non-viral gene transfection technologies for genetic engineering of stem cells. Eur J Pharm Biopharm. 2008;68:90\u2013104.","journal-title":"Eur J Pharm Biopharm"},{"key":"3989_CR16","doi-asserted-by":"publisher","first-page":"541","DOI":"10.6004\/jnccn.2021.0022","volume":"19","author":"AB Benson","year":"2021","unstructured":"Benson AB, D\u2019Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:541\u201365.","journal-title":"J Natl Compr Canc Netw"},{"key":"3989_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1080\/14737159.2020.1816170","volume":"20","author":"F Lopez-Campos","year":"2020","unstructured":"Lopez-Campos F, Linares-Espinos E, Maldonado PX, Sancho PG, Morgan TM, Martinez-Ballesteros C, et al. Genetic testing for the clinician in prostate cancer. Expert Rev Mol Diagn. 2020;20:933\u201346.","journal-title":"Expert Rev Mol Diagn"},{"key":"3989_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1471-2164-7-138","volume":"7","author":"I Braude","year":"2006","unstructured":"Braude I, Vukovic B, Prasad M, Marrano P, Turley S, Barber D, et al. Large scale copy number variation (CNV) at 14q12 is associated with the presence of genomic abnormalities in neoplasia. BMC Genomics. 2006;7:138.","journal-title":"BMC Genomics"},{"key":"3989_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/15384101.2016.1138183","volume":"15","author":"G Augello","year":"2016","unstructured":"Augello G, Puleio R, Emma MR, Cusimano A, Loria GR, McCubrey JA, et al. A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells. Cell Cycle. 2016;15:573\u201383.","journal-title":"Cell Cycle"},{"key":"3989_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24097905","author":"M Pan","year":"2023","unstructured":"Pan M, Sha Y, Qiu J, Chen Y, Liu L, Luo M, et al. RAD51 inhibition shows antitumor activity in hepatocellular carcinoma. Int J Mol Sci. 2023 ;24(9), 7905. https:\/\/doi.org\/10.3390\/ijms24097905","journal-title":"Int J Mol Sci"},{"key":"3989_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdy539","volume":"30","author":"DS Hong","year":"2019","unstructured":"Hong DS, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, et al. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019;30:325\u201331.","journal-title":"Ann Oncol"},{"key":"3989_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.2147\/IJGM.S347163","volume":"15","author":"W Li","year":"2022","unstructured":"Li W, Mei M, Liu T, Zhang S, Wang Z, Suo Y, et al. Identification of PDCD1 and PDCD1LG2 as prognostic biomarkers and associated with immune infiltration in hepatocellular carcinoma. Int J Gen Med. 2022;15:437\u201349.","journal-title":"Int J Gen Med"},{"key":"3989_CR23","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1038\/s41467-023-43462-1","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, Li K, Wang K, Yu H, Wang X, Shi M, et al. Low-dose radiotherapy combined with dual PD-L1 and VEGFA Blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells. Nat Commun. 2023;14:7709.","journal-title":"Nat Commun"},{"key":"3989_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ebiom.2019.03.022","volume":"42","author":"J Long","year":"2019","unstructured":"Long J, Wang A, Bai Y, Lin J, Yang X, Wang D, et al. Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. Ebiomedicine. 2019;42:363\u201374.","journal-title":"Ebiomedicine"},{"key":"3989_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.874805","volume":"13","author":"Y Yang","year":"2022","unstructured":"Yang Y, Qu Y, Li Z, Tan Z, Lei Y, Bai S. Identification of novel characteristics in TP53-mutant hepatocellular carcinoma using bioinformatics. Front Genet. 2022;13:874805.","journal-title":"Front Genet"},{"key":"3989_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.21037\/atm.2020.02.98","volume":"8","author":"M Shi","year":"2020","unstructured":"Shi M, Wang Y, Tang W, Cui X, Wu H, Tang Y, et al. Identification of TP53 mutation associated-immunotype and prediction of survival in patients with hepatocellular carcinoma. Ann Transl Med. 2020;8:321.","journal-title":"Ann Transl Med"},{"key":"3989_CR27","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","volume":"11","author":"Q Gou","year":"2020","unstructured":"Gou Q, Dong C, Xu H, Khan B, Jin J, Liu Q, et al. PD-L1 degradation pathway and immunotherapy for cancer. Cell Death Dis. 2020;11:955.","journal-title":"Cell Death Dis"},{"key":"3989_CR28","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2174\/1566524020666201015144702","volume":"21","author":"M Sopjani","year":"2021","unstructured":"Sopjani M, Morina R, Uka V, Xuan NT, Dermaku-Sopjani M. JAK2-mediated intracellular signaling. Curr Mol Med. 2021;21:417\u201325.","journal-title":"Curr Mol Med"},{"key":"3989_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102154","volume":"94","author":"MJ Duffy","year":"2021","unstructured":"Duffy MJ, O\u2019Grady S, Tang M, Crown J. MYC as a target for cancer treatment. Cancer Treat Rev. 2021;94:102154.","journal-title":"Cancer Treat Rev"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-025-03989-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-025-03989-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T09:57:42Z","timestamp":1760522262000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-025-03989-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3989"],"URL":"https:\/\/doi.org\/10.1186\/s12935-025-03989-3","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"18 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal experiments involved were reviewed by the Animal Ethics Committee of Capital Medical University (Ethics Approval Number: AEEI-2019-149, AEEI-2021-130).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We have obtained consents to publish this paper from all the participants of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"357"}}